Document resource
A new multimillion pound programme to test new obesity services and treatments, funded in part by the weight loss drug manufacturer Eli Lilly, could be seen as “marketing by another name,” public health experts have warned.
Annotated abstract
Industry funded NHS obesity programme raises “significant” conflict of interest concerns
bmj · 2025-08-22 · canonical JSON source